From Stigma to Acceptance: the Cultural and Medical Timeline of Coke Bottle Glasses
For some individuals with extreme diopter prescriptions, even the thinnest 1.74 aspheric glass remains an imperfect solution. A -12.00D prescription still introduces peripheral field narrowing, and high-index lenses naturally reflect more ambient light, demanding fragile anti-reflective treatments.
For decades, refractive surgery offered little comfort to this group. Corneal ablation techniques like PRK and LASIK work by vaporizing tissue to recontour the cornea. In severe myopia, removing enough corneal tissue to correct -10.00D risks destabilizing the eye’s structural wall, triggering corneal ectasia, irregular astigmatism, or permanent vision loss.
Cornea ----> [ ] (Left Intact)
Iris ----> |
ICL ----> [===] (Micro-thin Collamer Lens Placed in Sulcus)
Natural Lens->( O ) (Maintains Natural Accommodation)
This structural limitation explains the growing adoption of the implantable collamer lens (ICL). Approved by the FDA in the mid-2000s and refined through the EVO ICL platform in the 2020s, this procedure avoids corneal cutting entirely.
An ophthalmic surgeon creates a micro-incision at the corneal limbus and slides an ultra-flexible biocompatible collamer lens directly into the posterior chamber of the eye. Positioned just behind the colored iris and resting in front of the natural crystalline lens, the implant works like an internal contact lens. It requires zero corneal tissue removal, preserves natural accommodative focusing power, and can correct up to -20.00 diopters of myopia alongside severe astigmatism.
While the procedure carries real surgical risks, including intraocular infection, post-operative pressure spikes, and long-term endothelial cell loss that requires annual clinical monitoring, it has liberated thousands of severe myopes from the heavy eyewear that defined their early lives.